ADMA Biologics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2021 Annual Meeting of Stockholders held by ADMA Biologics, Inc. on May 27, 2021. The filing details the outcomes of three specific proposals submitted to security holders.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial performance data. The text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Voting Results
Three matters were voted upon and approved by stockholders:
- Director Election: Two Class II directors, Steven A. Elms and Adam S. Grossman, were elected to serve until the 2024 Annual Meeting.
- Capital Structure Change: Stockholders approved an amendment to the Second Amended and Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock from 150,000,000 to 300,000,000 shares.
- Auditor Ratification: The appointment of CohnReznick LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2021, was ratified.
Voting Statistics:
- Record Date: April 1, 2021.
- Shares Outstanding: 123,044,981.
- Shares Represented: 88,053,693 (constituting a quorum).
- Proposal 1 (Directors): Steven A. Elms received 55,871,445 votes "For"; Adam S. Grossman received 55,038,315 votes "For".
- Proposal 2 (Authorized Shares): 78,995,071 votes "For", 8,439,892 "Against", and 618,730 "Abstain".
- Proposal 3 (Auditor): 85,889,791 votes "For", 1,263,754 "Against", and 900,148 "Abstain".
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, or specific risk factors beyond the standard disclosure of the voting results.
Key Facts for Investor Verification
- Verify the effective date of the Certificate of Amendment increasing authorized shares to 300,000,000.
- Confirm the tenure of the newly elected Class II directors (Steven A. Elms and Adam S. Grossman) through the 2024 Annual Meeting.
- Review the full proxy statement for details on the rationale behind the increase in authorized shares.
- Check subsequent filings for the official filing of the Certificate of Amendment with the State of Delaware.